Skip to content
S

Sung-Kun Kim

Publications (3)

Modulation of Tumor Suppressor Genes by Histone Deacetylase Inhibitors in Cancer Therapy

Sung-Kun Kim, Nicol L. Nightingale, Kong K. Lee, Connor M. Ferlazzo, Lydia E. Neff & Jatindra N. Tripathy · Journal of Pharmaceutical Research International · 2024

Histone deacetylase (HDAC) inhibitors have emerged as promising therapeutics for various cancers due to their ability to modulate gene expression profiles and restore normal cellular functions. Among the key targets of HDAC inhibitors are tumor suppressor genes, which play crucia...

Open access Research Article 10.9734/jpri/2024/v36i117596

Potential Hexokinase II Inhibition by Benzimidazole Anthelmintics: Albendazole, Mebendazole and Fenbendazole

Hillary Le & Sung-Kun Kim · Journal of Pharmaceutical Research International · 2021

The nitrogen heterocycle benzimidazoles have been known to be anthelmintic drugs. Beyond that role, the benzimidazoles exhibit other pharmacological potential as anti-inflammatory, antiulcer, anti-hypertensive and anticancer agents. A growing body of evidence supports the antican...

Open access Research Article 10.9734/jpri/2020/v32i4631105

Inhibitory Effect on Hexokinase II by Benzimidazoles and the Insight into Interactions

Hillary J. Navarro, Jhawn G. Saul, Andrew E. Huckleby & Sung-Kun Kim · Journal of Pharmaceutical Research International · 2022

Background: Benzimidazoles are aromatic, heterocyclic organic molecules which exhibit pharmacological potential as anti-inflammatory, antiulcer, anti-hypertensive, anticancer agent, and anthelmintic treatments. The benzimidazoles could inhibit human hexokinase II, which is a crit...

Open access Research Article 10.9734/jpri/2022/v34i43A36311